Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer

Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer

Cellular organisms possess intricate DNA damage repair and tolerance pathways to manage various DNA lesions arising from endogenous or exogenous sources. The dysregulation of these pathways is associated with cancer development and progression. Synthetic lethality (SL), a promising cancer therapy co...

Full description

Bibliographic Details
Main Authors: Siddhant Bhoir, Oluwatobi Ogundepo, Xiuping Yu, Runhua Shi, Arrigo De Benedetti
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Biomedicines
Subjects:
PCa
synthetic lethality
TLK1 signaling
homologous recombination repair
TLK1 inhibitor J54
CPT-based PCa therapy
Online Access:https://www.mdpi.com/2227-9059/11/11/2987

Internet

https://www.mdpi.com/2227-9059/11/11/2987

Similar Items